发明授权
US09446019B2 Sparstolonin B based pharmaceutical agent for neuroblastoma treatment
有权
基于Sparstolonin B的药物治疗神经母细胞瘤
- 专利标题: Sparstolonin B based pharmaceutical agent for neuroblastoma treatment
- 专利标题(中): 基于Sparstolonin B的药物治疗神经母细胞瘤
-
申请号: US14483445申请日: 2014-09-11
-
公开(公告)号: US09446019B2公开(公告)日: 2016-09-20
- 发明人: Ambrish Kumar , Ugra Sen Singh , Daping Fan , Donald J. Dipette
- 申请人: University of South Carolina
- 申请人地址: US SC Columbia
- 专利权人: University of South Carolina
- 当前专利权人: University of South Carolina
- 当前专利权人地址: US SC Columbia
- 代理机构: Dority & Manning, P.A.
- 主分类号: A01N43/16
- IPC分类号: A01N43/16 ; A61K31/35 ; A61K31/353 ; A61K31/37
摘要:
Use of sparstolonin B in inhibition of growth and/or viability of human neuroblastoma cells is described. The sparstolonin B can be naturally derived from the Chinese herb Sparganium stoloniferum or can be synthetic. The sparstolonin B is shown to be effective both in vitro and in vivo in inhibition of growth and/or viability of neuroblastoma cells of multiple different genetic backgrounds including N-myc amplified with wild p53 neuroblastoma cells, N-myc amplified with mutated p53 neuroblastoma cells, and N-myc nonamplified neuroblastoma cells.
公开/授权文献
信息查询
IPC分类: